Analystreport

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $64.00 to $18.00. They now have a "buy"

Iovance Biotherapeutics, Inc.  (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com